BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eddy K, Chen S. Overcoming Immune Evasion in Melanoma. Int J Mol Sci 2020;21:E8984. [PMID: 33256089 DOI: 10.3390/ijms21238984] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Lin Y, Lee S, Cheng Y. Low-Level Laser Therapy Induces Melanoma Tumor Growth by Promoting Angiogenesis. Life 2023;13:320. [DOI: 10.3390/life13020320] [Reference Citation Analysis]
2 Hossain SM, Eccles MR. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance. Int J Mol Sci 2023;24. [PMID: 36675114 DOI: 10.3390/ijms24021601] [Reference Citation Analysis]
3 Remigante A, Spinelli S, Marino A, Pusch M, Morabito R, Dossena S. Oxidative Stress and Immune Response in Melanoma: Ion Channels as Targets of Therapy. Int J Mol Sci 2023;24. [PMID: 36614330 DOI: 10.3390/ijms24010887] [Reference Citation Analysis]
4 Li Y, Yun X, Li J, Bai M. CSTF2T up-regulates IGHG1 by binding to ZEB1 to promote melanoma cell proliferation, migration, and invasion. Tissue and Cell 2023. [DOI: 10.1016/j.tice.2023.102029] [Reference Citation Analysis]
5 Lehmann J, Caduff N, Krzywińska E, Stierli S, Salas-Bastos A, Loos B, Levesque MP, Dummer R, Stockmann C, Münz C, Diener J, Sommer L. Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma. Sci Adv 2023;9:eadc8825. [PMID: 36638181 DOI: 10.1126/sciadv.adc8825] [Reference Citation Analysis]
6 Jia Y, Shi K, Dai L, He X, Deng H, Han R, Yang F, Chu B, Liao J, Wei X, Qian Z. Gold Nanorods and Polymer Micelles Mediated Dual TLR Stimulators Delivery System CPG@Au NRs/M‐R848 Regulate Macrophages Reprogramming and DC Maturation for Enhanced Photothermal Immunotherapy of Melanoma. Small Methods 2022. [DOI: 10.1002/smtd.202201087] [Reference Citation Analysis]
7 Wu Z, Bian Y, Chu T, Wang Y, Man S, Song Y, Wang Z. The role of angiogenesis in melanoma: Clinical treatments and future expectations. Front Pharmacol 2022;13:1028647. [PMID: 36588679 DOI: 10.3389/fphar.2022.1028647] [Reference Citation Analysis]
8 Mercurio AC, Maniar AB, Wei AZ, Carvajal RD. Targeting the IL-2 pathway for the treatment of mucosal melanoma. Expert Opinion on Orphan Drugs 2022;10:34-47. [DOI: 10.1080/21678707.2022.2134776] [Reference Citation Analysis]
9 Mahdavi Gorabi A, Sadat Ravari M, Sanaei M, Davaran S, Kesharwani P, Sahebkar A. Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles. International Immunopharmacology 2022;113:109300. [DOI: 10.1016/j.intimp.2022.109300] [Reference Citation Analysis]
10 Tengda L, Cheng Q, Yi S, Qin S. Identification of Melanoma Subsets Based on DNA Methylation Sites and Construction of a Prognosis Evaluation Model. Journal of Oncology 2022;2022:1-15. [DOI: 10.1155/2022/6608650] [Reference Citation Analysis]
11 Xu J, Shi P, Xia F, Zhao X, Chen J, Geng R, Cui H, Yang L. RAI14 Promotes Melanoma Progression by Regulating the FBXO32/c-MYC Pathway. Int J Mol Sci 2022;23:12036. [PMID: 36233342 DOI: 10.3390/ijms231912036] [Reference Citation Analysis]
12 Wang Z, Yu Y, Wang C, Li J, Pang Y. Advances in the Application of Nanomaterials to the Treatment of Melanoma. Pharmaceutics 2022;14. [PMID: 36297527 DOI: 10.3390/pharmaceutics14102090] [Reference Citation Analysis]
13 Lopes J, Rodrigues CMP, Gaspar MM, Reis CP. Melanoma Management: From Epidemiology to Treatment and Latest Advances. Cancers 2022;14:4652. [DOI: 10.3390/cancers14194652] [Reference Citation Analysis]
14 Georgescu SR, Mitran CI, Mitran MI, Matei C, Constantin C, Neagu M, Tampa M. Apprising Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma—Persistent Updating. JPM 2022;12:1506. [DOI: 10.3390/jpm12091506] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Lv W, Zhan Y, Tan Y, Wu Y, Chen H. A combined aging and immune prognostic signature predict prognosis and responsiveness to immunotherapy in melanoma. Front Pharmacol 2022;13:943944. [DOI: 10.3389/fphar.2022.943944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hounye AH, Hu B, Wang Z, Wang J, Cao C, Zhang J, Hou M, Qi M. Evaluation of immunological characteristics and prognosis in melanoma patients using an endoplasmic reticulum stress-associated signature based on bioinformatic analysis.. [DOI: 10.21203/rs.3.rs-1866564/v1] [Reference Citation Analysis]
17 Wu X, Wang Y, Chen C, Xue Y, Zheng S, Cai L, Khawar MB. Hsa-let-7c-5p, hsa-miR-130b-3p, and hsa-miR-142-3p as Novel miRNA Biomarkers for Melanoma Progression. Genetics Research 2022;2022:1-12. [DOI: 10.1155/2022/5671562] [Reference Citation Analysis]
18 Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, Hashemi M, Kalu A, Zarrabi A, Nabavi N, Rabiee N, Sharifi E, Karimi-Maleh H, Ashrafizadeh M, Kumar AP, Wang Y. Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res 2022;41:214. [PMID: 35773731 DOI: 10.1186/s13046-022-02406-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
19 Shu X, Nie Z, Luo W, Zheng Y, Han Z, Zhang H, Xia Y, Deng H, Li F, Wang S, Zhao J, He L. Babesia microti Infection Inhibits Melanoma Growth by Activating Macrophages in Mice. Front Microbiol 2022;13:862894. [DOI: 10.3389/fmicb.2022.862894] [Reference Citation Analysis]
20 Aspenström P. The Role of Fast-Cycling Atypical RHO GTPases in Cancer. Cancers (Basel) 2022;14:1961. [PMID: 35454871 DOI: 10.3390/cancers14081961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Feng S, Zhou Y, Huang H, Lin Y, Zeng Y, Han S, Huang K, Liu Q, Zhu W, Yuan Z, Liang B. Nobiletin Induces Ferroptosis in Human Skin Melanoma Cells Through the GSK3β-Mediated Keap1/Nrf2/HO-1 Signalling Pathway. Front Genet 2022;13:865073. [PMID: 35350242 DOI: 10.3389/fgene.2022.865073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Loya A, Gombos DS, Patel SP. Second Primary Malignancies in Patients With Melanoma Subtypes: Analysis of 120,299 Patients From the SEER Database (2000-2016). Front Oncol 2022;12:853076. [DOI: 10.3389/fonc.2022.853076] [Reference Citation Analysis]
23 Guo X, Fang Y, Guo C, Jia Q, Chi Z, Li J, Qin R, Tian J, Fan R. Qa-1b functions as an oncogenic factor in mouse melanoma cells. Journal of Dermatological Science 2022. [DOI: 10.1016/j.jdermsci.2022.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Comito F, Pagani R, Grilli G, Sperandi F, Ardizzoni A, Melotti B. Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma. Cancers (Basel) 2022;14:271. [PMID: 35053435 DOI: 10.3390/cancers14020271] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
25 Amweg A, Tusup M, Cheng P, Picardi E, Dummer R, Levesque MP, French LE, Guenova E, Läuchli S, Kundig T, Mellett M, Pascolo S. The A to I editing landscape in melanoma and its relation to clinical outcome. RNA Biol 2022;19:996-1006. [PMID: 35993275 DOI: 10.1080/15476286.2022.2110390] [Reference Citation Analysis]
26 Du F, Li H, Li Y, Liu Y, Li X, Dang N, Chu Q, Yan J, Fang Z, Wu H, Zhang Z, Zhu X, Li X. Identification of m6A Regulator-Associated Methylation Modification Clusters and Immune Profiles in Melanoma. Front Cell Dev Biol 2021;9. [DOI: 10.3389/fcell.2021.761134] [Reference Citation Analysis]
27 Chen ZY, Huang JQ, Zhu Y, Chen YS, Yu XF. Comprehensive Analysis of the Immune Implication of TEX41 in Skin Cutaneous Melanoma. Dis Markers 2021;2021:2409820. [PMID: 34795805 DOI: 10.1155/2021/2409820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Catalani E, Giovarelli M, Zecchini S, Perrotta C, Cervia D. Oxidative Stress and Autophagy as Key Targets in Melanoma Cell Fate. Cancers (Basel) 2021;13:5791. [PMID: 34830947 DOI: 10.3390/cancers13225791] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
29 Matias M, Pinho JO, Penetra MJ, Campos G, Reis CP, Gaspar MM. The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval. Cells 2021;10:3088. [PMID: 34831311 DOI: 10.3390/cells10113088] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
30 da Silva GB, Yamauchi MA, Zanini D, Bagatini MD. Novel possibility for cutaneous melanoma treatment by means of rosmarinic acid action on purinergic signaling. Purinergic Signal 2021. [PMID: 34741236 DOI: 10.1007/s11302-021-09821-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Fink M, Vittrup AS, Bastholt L, Svane IM, Donia M, Luczak AA, Ruhlmann CH, Guldbrandt LM, Koehler UH, Winther ML, Ellebaek E, Haslund CA, Schmidt H. Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. Cancers (Basel) 2021;13:5550. [PMID: 34771712 DOI: 10.3390/cancers13215550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Jęśkowiak I, Wiatrak B, Szeląg A, Mączyński M. Preclinical Study of Immunological Isoxazole Derivatives as a Potential Support for Melanoma Chemotherapy. Int J Mol Sci 2021;22:10920. [PMID: 34681580 DOI: 10.3390/ijms222010920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Tufano M, Cesaro E, Martinelli R, Pacelli R, Romano S, Romano MF. FKBP51 Affects TNF-Related Apoptosis Inducing Ligand Response in Melanoma. Front Cell Dev Biol 2021;9:718947. [PMID: 34589486 DOI: 10.3389/fcell.2021.718947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Hamieh M, Chatillon JF, Dupel E, Bayeux F, Fauquembergue E, Maby P, Drouet A, Duval-Modeste AB, Adriouch S, Boyer O, Latouche JB. Generation of Pure Highly Functional Human Anti-Tumor Specific Cytotoxic T Lymphocytes With Stem Cell-Like Memory Features for Melanoma Immunotherapy. Front Immunol 2021;12:674276. [PMID: 34566953 DOI: 10.3389/fimmu.2021.674276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Dobre EG, Constantin C, Costache M, Neagu M. Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma. J Pers Med 2021;11:901. [PMID: 34575678 DOI: 10.3390/jpm11090901] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
36 Eddy K, Chen S. Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma. Cancers (Basel) 2021;13:3874. [PMID: 34359771 DOI: 10.3390/cancers13153874] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Revythis A, Shah S, Kutka M, Moschetta M, Ozturk MA, Pappas-Gogos G, Ioannidou E, Sheriff M, Rassy E, Boussios S. Unraveling the Wide Spectrum of Melanoma Biomarkers. Diagnostics (Basel) 2021;11:1341. [PMID: 34441278 DOI: 10.3390/diagnostics11081341] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 15.0] [Reference Citation Analysis]
38 Saellstrom S, Sadeghi A, Eriksson E, Segall T, Dimopoulou M, Korsgren O, Loskog AS, Tötterman TH, Hemminki A, Ronnberg H. Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up. Front Vet Sci 2021;8:695222. [PMID: 34368282 DOI: 10.3389/fvets.2021.695222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
39 Trappetti V, Fazzari JM, Fernandez-Palomo C, Scheidegger M, Volarevic V, Martin OA, Djonov VG. Microbeam Radiotherapy-A Novel Therapeutic Approach to Overcome Radioresistance and Enhance Anti-Tumour Response in Melanoma. Int J Mol Sci 2021;22:7755. [PMID: 34299373 DOI: 10.3390/ijms22147755] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
40 Fejza A, Polano M, Camicia L, Poletto E, Carobolante G, Toffoli G, Mongiat M, Andreuzzi E. The Efficacy of Anti-PD-L1 Treatment in Melanoma Is Associated with the Expression of the ECM Molecule EMILIN2. Int J Mol Sci 2021;22:7511. [PMID: 34299131 DOI: 10.3390/ijms22147511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
41 Furue M, Furue M. OX40L-OX40 Signaling in Atopic Dermatitis. J Clin Med 2021;10:2578. [PMID: 34208041 DOI: 10.3390/jcm10122578] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
42 Hwang J, Zhang W, Dhananjay Y, An EK, Kwak M, You S, Lee PC, Jin JO. Astragalus membranaceus polysaccharides potentiate the growth-inhibitory activity of immune checkpoint inhibitors against pulmonary metastatic melanoma in mice. Int J Biol Macromol 2021;182:1292-300. [PMID: 34000307 DOI: 10.1016/j.ijbiomac.2021.05.073] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
43 Eddy K, Shah R, Chen S. Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities. Front Oncol 2020;10:626129. [PMID: 33614507 DOI: 10.3389/fonc.2020.626129] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 11.0] [Reference Citation Analysis]